Patents Assigned to Salmedix, Inc.
  • Methods and compositions for the treatment of chronic lymphocytic leukemia
    Patent number: 6921772
    Abstract: The level of the leukemic lymphocytes in patients suffering from chronic lymphocytic leukemia (CLL) is reduced by the administration of certain indole or carbazole compounds, such as the nonsteroidal anti-inflammatory drug etodolac or related indole or carbazole compounds.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: July 26, 2005
    Assignee: Salmedix, Inc.
    Inventor: Francis A. Nardella
  • Methods for inhibiting protein kinases in cancer cells
    Publication number: 20040096436
    Abstract: The present invention provides methods of treating cancer using inhibitors of protein kinases. The inhibitors of protein kinases are combined with agents that inhibit a cellular ATP synthetic pathway. Inhibitors of ATP synthesis include inhibitors of de novo purine biosynthesis, inhibitors of the salvage pathway of ATP biosynthesis, and inhibitors of the enzyme inosine monophosphate dehydrogenase.
    Type: Application
    Filed: August 1, 2003
    Publication date: May 20, 2004
    Applicants: REGENTS OF THE UNIVERSITY OF CALIFORNIA, SALMEDIX, INC.
    Inventors: Dennis A. Carson, Michael D. Rosenbach, Carlos J. Carrera, Lorenzo M. Leoni
  • Methods and compositions for the treatment of chronic lymphocytic leukemia
    Patent number: 6573292
    Abstract: Methods for the treatment of Chronic Lymphocytic Leukemia and B-cell and T-cell lymphomas are provided. These methods comprise administering to a patient in need of treatment an effective amount of certain indole and carbazole compounds, such as etodolac.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: June 3, 2003
    Assignee: Salmedix, Inc.
    Inventor: Francis A. Nardella